ClinicalTrials.gg
RecruitingNCT07378839Updated Mar 19, 2026

Alternate Nostril Breathing (ANB) for 1st Trimester Nausea and Vomiting

An interventional study of Alternate Nostril Breathing in Pregnancy Emesis and Nausea, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by University of Minnesota · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This is a prospective, two-arm, non-blinded randomized controlled study designed to evaluate the effects of a one-week alternate nostril breathing (ANB) intervention on nausea and vomiting severity in pregnant individuals during their first trimester.

02

Conditions studied

  • Pregnancy Emesis
  • Nausea

Browse trials for

03

In context

Nausea

644 studies on the registry are indexed under Nausea; 85 are open to participants now.

This study's planned enrollment of 100 is close to the median of 96 across 544 interventional studies indexed under Nausea.

Browse Nausea studies →

Lead sponsor

University of Minnesota is the lead sponsor of 1,216 studies on the registry; 197 are open to participants now.

Of its 136 completed or terminated interventional studies of FDA-regulated products, 95 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant individuals aged 18 years or older
  • Viable pregnancy with a gestational age between 6 0/7 - 12 6/7 weeks of gestation, confirmed by last menstrual period or ultrasound
  • Diagnosed with mild to moderate NVP (PUQE-24 score between 4-12)
  • Ability to understand and read English

Exclusion criteria

Exclusion Criteria:

  • Severe nausea and vomiting, defined as a PUQE score >12, or diagnosis of hyperemesis gravidarum requiring hospitalization or intravenous fluid therapy
  • Pre-existing, active or acute respiratory conditions (e.g., asthma, )
  • History of severe anxiety disorders affecting breathing patterns
  • Known deviated nasal septum
  • Nausea and vomiting that pre-dates the pregnancy or is suspected to be due to a etiology other than pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Alternate Nostril Breathing

    Participants in the intervention group will receive a brief orientation via a research team member at the time of randomization on alternate nostril breathing (ANB) and then be provided with a written and video-based instructional guide. They will be instructed to perform ANB 3 times per day for 5-10 minutes per session over a 7-day period and document their sessions in a daily symptom diary. The 7-day period will begin the following day after enrollment to allow for a full day of intervention implementation (Day 1-7).

    Behavioral: Alternate Nostril Breathing

  • No intervention
    Usual Care Only

    This group will receive usual care and complete a daily symptom diary for Day 1-7.

Interventions

  • BehavioralAlternate Nostril Breathing

    ANB 3 times per day for 5-10 minutes per session over a 7-day period

06

What researchers measure

Primary outcomes

  1. Severity of Nausea and Vomiting

    Measured by the change in the Pregnancy-Unique Quantification of Emesis and Nausea (PUQE) score, where scores range from 3-15, and a higher score indicates greater severity of nausea and vomiting.

    Time frame: Day 7

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07378839
Responsible party
Sponsor
First posted
Jan 30, 2026
Start date
Feb 10, 2026
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Mar 19, 2026

Study contacts

Erin Wesley
Contact
obgynresearch@umn.edu
612-624-9208
Shilpa Babbar
principal investigator · University of Minnesota

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion